Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter Reports Surge in Net Income; Revenue, R&D Grows

NEW YORK, July 26 - Beckman Coulter today reported a 4-percent increase in second-quarter revenue, a nudge up in R&D spending, and a strong jump in net income.


For the period ended June 30, the life-sciences tool giant posted an increase in total revenues to just over $516 million from $496 million one year ago. Sales of its clinical diagnostic products inched up 6 percent year over year to $356 million, and sales of its automated genetic-analysis tools jumped 15 percent from the second quarter last year to $43.7 million, the company said.


R&D spending saw a slight increase, to $47.8 million from $47.3 million in the same period one year ago. Second quarter net income, meantime, grew 14 percent to $41.9 million, or $.64 per share, from $36.8 million, or $.58 per share, year over year, the company said.


Beckman Coulter said it had roughly $42.5 million in cash and equivalents as of June 30, 2002, compared with $36 million in the same period one year ago.


Click here for more information.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.